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Aim
We aimed to assess the association between pre-treatment computed tomography (CT) 
body composition measurements and chemotherapy intolerance in patients with head 
and neck cancer (HNC).
Conclusion
Lower pre-treatment values of skeletal muscle index (SMI) at T4 and L3 level are 
associated with higher occurrence of chemotherapy intolerance in HNC patients, 
suggesting that taking into account SMI may help preventing chemotherapy intolerance. 
Rationale
It is unclear whether muscle mass 
depletion is associated with chemotherapy 
intolerance in patients with head and neck 
cancer (HNC).
Results
• Inclusion: n=218 (age: 57.8±10.3 years, 
male: 78%). T4 image: n=97, L3 image: 
n=121. 
• Univariate analysis: no significant 
association between chemotherapy 
intolerance and SMI (p=0.109, OR=0.98 
[0.96-1.00]) or skeletal muscle radiation 
attenuation (MA: p=0.547, OR=0.99 
[0.96-1.02]). 
• Multivariate analysis: significant 
association between SMI and chemo-
therapy intolerance (p=0.002, OR 0.95 
[0.91-0.98]). 
• SCAD model included type of chemo-
therapy, body mass index (BMI), 
interaction between smoking and 
drinking, and comorbidity. 
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Figure 1a. Merged SMI (L3 and T4), BMI and chemotherapy 
intolerance in 170 HNC patients treated with cisplatin 
Methods
• Design: retrospective analysis of data 
from oncological database of Northern 
Alberta, Canada. 
• Patients: adult HNC patients with 
(surgery and) platin-based chemo-
radiotherapy. Provided availability of pre-
treatment CT scan at T4 or L3 level. 
• Measurements: body composition 
evaluated by assessment of SMI 
(cm2/m2) and skeletal muscle radiation 
attenuation (Hounsfield Units). SMI and 
MA were corrected for deviation from the 
mean to enable merged T4 and L3 
measurements
• Chemotherapy intolerance: considered 
present if unplanned reduction or 
termination in chemotherapy regime 
ascribed to toxicity. 
• Analysis: univariate and multivariate 
logistic regression analyses with SCAD 
best model selection. 
Multivariate analysis corrected for age, 
sex, smoking, drinking, body weight, 
BMI, comorbidity, location and stage of 
cancer, type of treatment and chemo-
therapy, and time between CT scan and 
start of chemo-radiotherapy. 
A p-value <0.05 was considered 
significant. Odds Ratios (OR) [95% CI] 
were presented.
Figure 1b. Merged SMI (L3 and T4), BMI and chemotherapy 
intolerance in 48 HNC patients treated with carboplatin
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